CEPHULAC
LOE ApproachingNDAORAL, RECTALSOLUTIONPriority Review
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 33m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEPHULAC is an oral and rectal solution small molecule approved in 1976 by Sanofi. The mechanism of action and specific indications are not publicly detailed in available data, but it represents a legacy therapeutic with established clinical use.
LOE Approaching
As LOE approaches, the commercial team is likely focused on lifecycle extension, generic preparedness, and cost optimization rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEPHULAC presents limited near-term career growth opportunities due to its LOE-approaching lifecycle stage and zero linked job postings. Roles available are primarily defensive—focused on generic preparation, reimbursement retention, and market share protection rather than expansion or innovation.
Brand ManagerMarket Access Manager
Worked on CEPHULAC at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.